A Pfizer-BioNTech COVID-19 vaccine trial for children aged between five and 11 has produced “positive results” and has shown a “robust immune response”, the two firms have said.They said the results are the first to emerge from any vaccine trial for children aged below 12 and would “provide a strong foundation” for seeking the authorisation of its potential rollout across the world.
Pfizer and BioNTech said the data will be submitted to health regulatory bodies and that they believe the trial provides a “great opportunity” to prevent COVID-19 in younger age groups.
Please use Chrome browser for a more accessible video …
